Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M157Revenue $M8.0Net Margin (%)-715.6Z-Score-16.6
Enterprise Value $M124EPS $-0.7Operating Margin %-607.6F-Score3
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-715.6Higher ROA y-yN
Price/Book42.210-y EBITDA Growth Rate %-41.4Quick Ratio1.2Cash flow > EarningsY
Price/Sales21.45-y EBITDA Growth Rate %-29.4Current Ratio1.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-92.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-734.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M62.0ROI % (ttm)-267.8Gross Margin Increase y-yN

Gurus Latest Trades with SNSS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNSSJean-Marie Eveillard 2014-09-30 Sold Out $5.553 - $8.23
($6.91)
$ 2.53-63%Sold Out0
SNSSJean-Marie Eveillard 2013-09-30 Buy $4.55 - $6.05
($5.08)
$ 2.53-50%New holding, 200000 sh.200,000
SNSSJean-Marie Eveillard 2013-03-31 Sold Out -0.01%$4 - $6.49
($5.21)
$ 2.53-51%Sold Out0
SNSSJean-Marie Eveillard 2012-09-30 Reduce$2.95 - $5.76
($3.55)
$ 2.53-29%Reduce -30.24%350,000
SNSSJean-Marie Eveillard 2012-06-30 Buy 0.01%$2.51 - $3.18
($2.78)
$ 2.53-9%New holding, 501727 sh.501,727
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNSS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNSS Jean-Marie Eveillard 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SNSS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BARRIS PETER J10% Owner 2014-08-29Sell266,700$7.97-68.26view
BARRETT M JAMES10% Owner 2014-08-29Sell266,700$7.97-68.26view
Growth Equity Opportunities Fu10% Owner 2014-08-29Sell266,700$7.97-68.26view
SANDELL SCOTT D10% Owner 2014-08-29Sell266,700$7.97-68.26view
KOLLURI KRISHNA KITTU10% Owner 2014-08-29Sell266,700$7.97-68.26view
KERINS PATRICK J10% Owner 2014-08-29Sell266,700$7.97-68.26view
DRANT RYAN D10% Owner 2014-08-29Sell266,700$7.97-68.26view
BASKETT FOREST10% Owner 2014-08-29Sell266,700$7.97-68.26view
Misfeldt DaytonDirector, 10% Owner 2014-08-28Sell300,700$7.98-68.3view
BAY CITY CAPITAL LLC10% Owner 2014-08-28Sell300,700$7.98-68.3view

Press Releases about SNSS :

    Quarterly/Annual Reports about SNSS:

    News about SNSS:

    Articles On GuruFocus.com
    comment on SNSS Mar 02 2013 
    Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
    Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
    cooldecency99 note on SNSS May 01 2010 
    Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
    Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
    Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
    Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
    Sunesis Reports Financial Results for the Second Quarter 2009 Jul 29 2009 

    More From Other Websites
    SUNESIS PHARMACEUTICALS INC Financials Dec 16 2014
    Sunesis Pharma upgraded by ROTH Capital Dec 15 2014
    Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial... Dec 08 2014
    Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial... Dec 08 2014
    Sunesis Spin Doctor Tiptoes Around Failed Leukemia Drug Trial Dec 07 2014
    Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual... Dec 07 2014
    Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following... Dec 02 2014
    Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following... Dec 02 2014
    Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology Nov 24 2014
    Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology Nov 24 2014
    Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica Nov 19 2014
    Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica Nov 19 2014
    SUNESIS PHARMACEUTICALS INC Financials Nov 18 2014
    Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% Nov 18 2014
    Is This the Sunesis Resurrection? Nov 17 2014
    Sunesis Pharmaceuticals Bounces On Results Announcement Nov 17 2014
    Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of Blood Cancer Treatment Data Nov 17 2014
    Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual... Nov 17 2014
    Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual... Nov 17 2014
    10-Q for Sunesis Pharmaceuticals, Inc. Nov 12 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK